155 related articles for article (PubMed ID: 9588228)
1. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
[TBL] [Abstract][Full Text] [Related]
2. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
4. [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
Inoue C; Kato S; Higuchi K; Inoue H
Nihon Kokyuki Gakkai Zasshi; 2007 Mar; 45(3):243-7. PubMed ID: 17419436
[TBL] [Abstract][Full Text] [Related]
5. [A case of desmoplastic malignant mesothelioma with elevated serum CYFRA 21-1].
Nakamura H; Kitada O; Aragane K; Miyata S; Kodama T; Kuribayashi K; Nakagomi T; Takenaka N; Jin S; Nagasawa M; Sugita M
Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):337-40. PubMed ID: 12096506
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
Schouwink H; Korse CM; Bonfrer JM; Hart AA; Baas P
Lung Cancer; 1999 Jul; 25(1):25-32. PubMed ID: 10466859
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.
Filiberti R; Parodi S; Libener R; Ivaldi GP; Canessa PA; Ugolini D; Bobbio B; Marroni P
Med Oncol; 2013 Jun; 30(2):543. PubMed ID: 23532816
[TBL] [Abstract][Full Text] [Related]
8. [A case of diffuse pulmonary metastasis of malignant pleural mesothelioma with elevated CYFRA in serum and pleural effusion].
Saito K; Koyama N; Tanaka M; Usui H; Tojou N; Miyasato I; Marushige F; Inase N; Ichioka M
Nihon Naika Gakkai Zasshi; 1998 Oct; 87(10):2084-5. PubMed ID: 9867019
[No Abstract] [Full Text] [Related]
9. Cytokeratin markers in malignant pleural mesothelioma.
Nisman B; Barak V; Heching N; Kramer M; Reinus C; Lafair J
Cancer Detect Prev; 1998; 22(5):416-21. PubMed ID: 9727622
[TBL] [Abstract][Full Text] [Related]
10. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
Salama G; Miédougé M; Rouzaud P; Mauduyt MA; Pujazon MC; Vincent C; Carles P; Serre G
Br J Cancer; 1998; 77(3):472-6. PubMed ID: 9472646
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of tissue polypeptide antigen in pleural effusions with malignant pleural mesothelioma].
Tokuyama T; Yoneda T; Hamada K; Yoshikawa M; Fu A; Tomoda K; Nakaya M; Narita N; Tamura M; Kitamura K
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Jan; 33(1):39-43. PubMed ID: 7699966
[TBL] [Abstract][Full Text] [Related]
13. The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma.
Joglekar VM; Oliver D; Harris M
Br J Ind Med; 1991 Jan; 48(1):34-7. PubMed ID: 1704251
[TBL] [Abstract][Full Text] [Related]
14. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
15. Tissue polypeptide antigen (TPA) in pleural effusions.
Parazzi F; Faravelli B; Gallo L; Nosenzo M; Razzetti A; Barone D; Bandelloni R; D'Amore E
Tumori; 1987 Feb; 73(1):33-6. PubMed ID: 2435037
[TBL] [Abstract][Full Text] [Related]
16. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
20. The established and future biomarkers of malignant pleural mesothelioma.
Panou V; Vyberg M; Weinreich UM; Meristoudis C; Falkmer UG; Røe OD
Cancer Treat Rev; 2015 Jun; 41(6):486-95. PubMed ID: 25979846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
